AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 81 min read$BLLN

Atay Oguzhan sold $3.2M of BLLN

Atay Oguzhan (Chairman and CEO) sold 26,250 shares of BillionToOne, Inc. (BLLN) at an average of $122.05 ($118.49–$124.61, $3.20M total) across 14 trades on 2026-07-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Atay Oguzhan
Published Jul 8, 2026, 11:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 8, 2026, 11:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
medium confidence
Mentioned
$BLLN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale size, price range, and post-transaction holdings (0 shares) by the CEO/Chairman under a 10b5-1 plan.

02

Market read

Traders may monitor for sentiment/positioning effects, but there is no accompanying fundamental catalyst in the filing.

03

What to watch

The CEO ended with 0 shares, which can be interpreted as a stronger sentiment signal than typical partial sales, even if the plan was pre-arranged.

Relevance 5/10Novelty 5/10Timing: Filed after-hours on 2026-07-08, reflecting trades dated 2026-07-06.

Background

The article is an SEC Form 4 insider transaction disclosure for BillionToOne, Inc. (BLLN).

Company-level read

Ticker impact

$BLLNNeutralMedium confidence
Context

BillionToOne CEO/Chairman Atay Oguzhan sold 26,250 shares in open-market trades totaling about $3.2M, leaving 0 shares.

Expected impact

Likely limited immediate price impact; any effect is more sentiment/flow related than fundamentals.

Evidence & confidence

The filing is a primary Form 4 disclosure with a stated pre-arranged 10b5-1 plan, and it does not include new operating or guidance information.

Market effects

Sector

Minimal sector read-through; this is company-specific insider activity without new clinical, regulatory, or commercial datapoints.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A 10b5-1 sale can be purely planned liquidity, so the market may overreact if it treats it as a signal of deteriorating fundamentals.

Key entities

  • issuer
    BillionToOne, Inc.

    Subject of the Form 4 insider sale disclosure.

  • insider
    Atay Oguzhan

    Chairman and CEO who executed the open-market sale under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BLLN insider trading history →

Related articles

OCT 7
$BLLNLow

BillionToOne's Northstar Response Shows High Concordance In Advanced Cancer Study

BillionToOne (BLLN) published a study showing its Northstar Response liquid biopsy assay had high concordance with a commercial ctDNA assay in advanced cancer patients. The study of 61 patients found 94% agreement in tumor burden change direction, with Northstar Response aligning with clinical ground truth in discordant cases. The assay detects disease progression even when tumors evolve post-biopsy. BLLN shares closed at $22.71, down 0.79%.

rttnews.com2 min
OCT 7
$BLLNMedAI 8/10

BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

BillionToOne (BLLN) announced a peer-reviewed study showing its Northstar Response® liquid biopsy assay performed on par or better than a tumor-informed assay in tracking cancer treatment. The study, published in The Journal of Liquid Biopsy, evaluated 169 samples from 61 patients, finding close alignment in results (R² = 0.97) and agreement in 94% of cases. Northstar Response detected disease progression in cases where the tumor-informed assay did not, highlighting its tumor-agnostic benefits.

globenewswire.com2 min
AUG 6
$BLLNMedAI 8/10

BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move - BillionToOne (NASDAQ:BLLN)

BillionToOne (NASDAQ:BLLN) shares fell 28.12% in after-hours after reporting Q2 results. For the quarter ended June 30, 2026, revenue rose to $109.4M from $66.6M, net income was $8.1M ($0.15/share), and gross margin improved to 70%. The company kept 2026 revenue guidance of $450M to $465M and plans Unity Fetal Risk Screen (Aug. 17) and Northstar Origin (Sept. 1) launches.

benzinga.com3 min
AUG 5
$BLLNMed

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

BillionToOne, Inc. (BLLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance MENLO PARK, CA, August 5, 2026 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to al

SEC EDGAR 8-K7 min
MAY 27
$BLLNMedAI 8/10

Billiontoone (BLLN) – Research Analysts’ Recent Ratings Updates

BillionToOne (NASDAQ: BLLN) saw multiple analyst rating and target changes. Weiss Ratings upgraded BLLN to “sell (d+)” (from “sell (d)”) on 5/15 and reaffirmed “sell (d)” on 5/1. Guggenheim raised its target to $120 (from $100) and kept a “buy” on 5/13. JPMorgan lifted its target to $125 and maintained “overweight” on 5/7. BTIG cut its target to $130 (from $140) while keeping “buy” on 5/7.

dailypolitical.com1 min